As Quotient LTD (QTNT) Valuation Rose, Shareholder Highbridge Capital Management LLC Has Cut Holding by $3.28 Million

Quotient Limited (NASDAQ:QTNT) LogoInvestors sentiment increased to 2.55 in Q2 2019. Its up 0.50, from 2.05 in 2019Q1. It is positive, as 9 investors sold QTNT shares while 11 reduced holdings. 26 funds opened positions while 25 raised stakes. 45.71 million shares or 50.13% more from 30.45 million shares in 2019Q1 were reported. Lombard Odier Asset Management (Usa) invested in 320,000 shares or 0.24% of the stock. Trexquant Limited Partnership holds 13,206 shares or 0.01% of its portfolio. Mirae Asset Glob Invests invested in 0% or 75,000 shares. Ameriprise Financial Inc holds 2.93M shares. River & Mercantile Asset Management Llp has 145,010 shares for 0.19% of their portfolio. Gilder Gagnon Howe And has 447,361 shares for 0.04% of their portfolio. Royal Bank Of Canada reported 2,256 shares. Bnp Paribas Arbitrage invested 0% in Quotient Limited (NASDAQ:QTNT). Park West Asset Mngmt Limited Co has invested 0.41% in Quotient Limited (NASDAQ:QTNT). Cubist Systematic Strategies Limited Liability Company invested in 40,997 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% of its portfolio in Quotient Limited (NASDAQ:QTNT). Swiss Bancorporation has invested 0% of its portfolio in Quotient Limited (NASDAQ:QTNT). Wells Fargo And Mn holds 0% or 5,885 shares. Essex Com Lc invested 0.19% of its portfolio in Quotient Limited (NASDAQ:QTNT). Farallon Cap Mngmt Limited Co holds 0.19% or 2.50M shares in its portfolio.

Since June 13, 2019, it had 1 insider buy, and 0 selling transactions for $27,405 activity.

Highbridge Capital Management Llc decreased its stake in Quotient Ltd (QTNT) by 15.55% based on its latest 2019Q2 regulatory filing with the SEC. Highbridge Capital Management Llc sold 364,311 shares as the company’s stock rose 32.00% . The hedge fund held 1.98 million shares of the in vitro & in vivo diagnostic substances company at the end of 2019Q2, valued at $18.50M, down from 2.34 million at the end of the previous reported quarter. Highbridge Capital Management Llc who had been investing in Quotient Ltd for a number of months, seems to be less bullish one the $580.84 million market cap company. The stock decreased 4.67% or $0.43 during the last trading session, reaching $8.77. About 505,071 shares traded or 53.84% up from the average. Quotient Limited (NASDAQ:QTNT) has risen 40.80% since September 13, 2018 and is uptrending. It has outperformed by 40.80% the S&P500.

Highbridge Capital Management Llc, which manages about $32.39B and $1.51B US Long portfolio, upped its stake in Dbx Etf Tr (Call) (ASHR) by 200,000 shares to 400,000 shares, valued at $11.26 million in 2019Q2, according to the filing. It also increased its holding in Barclays Bk Plc (Put) by 200,000 shares in the quarter, for a total of 875,000 shares, and has risen its stake in Tesla Inc (NASDAQ:TSLA).

Analysts await Quotient Limited (NASDAQ:QTNT) to report earnings on November, 4. They expect $-0.40 EPS, up 24.53 % or $0.13 from last year’s $-0.53 per share. After $-0.36 actual EPS reported by Quotient Limited for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

More notable recent Quotient Limited (NASDAQ:QTNT) news were published by: which released: “Quotient prices common stock offering – Seeking Alpha” on December 07, 2018, also with their article: “Quotient Limited Announces Initial MosaiQâ„¢ SDS Verification and Validation Data – GlobeNewswire” published on December 03, 2018, published: “Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call – GlobeNewswire” on May 14, 2019. More interesting news about Quotient Limited (NASDAQ:QTNT) were released by: and their article: “Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares – GlobeNewswire” published on December 06, 2018 as well as‘s news article titled: “FDA approves Quotient’s seven additional blood bank reagents – Seeking Alpha” with publication date: May 21, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.